急性冠脉综合征相关血清学标志物研究进展
Advances in Serological Markers Associated with Acute Coronary Syndrome
摘要: 急性冠脉综合征(ACS)是由急性心肌缺血引起的一组临床综合征,具有起病急、病情变化快、病死率高等特点,主要包括ST段抬高型心肌梗死(STEMI)、非ST段抬高型心肌梗死(NSTEMI)和不稳定性心绞痛(UA)。临床表现为胸骨后闷痛、恶心、呼吸困难、窒息感等,严重者甚至会晕厥,严重影响患者的生活质量。急性冠脉综合征的血清标志物主要有肌钙蛋白、超敏C反应蛋白、高迁移率族蛋白B1、脑钠肽。心肌肌钙蛋白水平与急性心肌梗死的发病有显著的相关性,能敏感地反应心肌损伤,是诊断心肌缺血的首选标志物。超敏C反应蛋白是由肝脏合成的一种全身性炎症反应急性期的非特异性标志物,与心血管疾病的发生有着密切的关系。高迁移率族蛋白B1是近几年发现的一种致炎细胞因子,参与了诸多炎症免疫应答。脑钠肽是是反应心功能的可靠指标,是急性冠脉综合征患者死亡最强大的预测物。
Abstract: Acute Coronary Syndromes (ACS), a group of clinical syndromes caused by acute myocardial ische-mia, are characterized by rapid onset, rapid disease change and high mortality, mainly including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarc-tion (NSTEMI) and unstable angina pectoris (UA). Clinical manifestations include poststernal pain, nausea, dyspnea, asphyxia, etc., and even syncope in severe cases, which seriously affects patients’ quality of life. The main serum markers of acute coronary syndrome were troponin, hypersensitive C-reactive protein, high mobility group protein B1 and brain natriuretic peptide. Myocardial tro-ponin level has a significant correlation with the incidence of acute myocardial infarction, can sensi-tively reflect myocardial injury, and is the preferred marker for the diagnosis of myocardial ische-mia. Hypersensitive C-reactive protein is a nonspecific marker of the acute phase of systemic in-flammatory response synthesized by the liver, which is closely related to the occurrence of cardio-vascular diseases. High mobility group protein B1 is a kind of inflammatory cytokine discovered in recent years, which is involved in many inflammatory immune responses. Brain natriuretic peptide is a reliable indicator of cardiac function and the strongest predictor of death in patients with acute coronary syndrome.
文章引用:刘嘉. 急性冠脉综合征相关血清学标志物研究进展[J]. 临床医学进展, 2023, 13(4): 6291-6295. https://doi.org/10.12677/ACM.2023.134885

参考文献

[1] 翟明霞, 李文芳. 替格瑞洛联合阿托伐他汀治疗急性冠状动脉综合征临床研究[J]. 中国药业, 2020, 29(2): 86-88.
[2] Virani, S.S., Alvaro, A., Aparicio, H.J., et al. (2021) Heart Disease and Stroke Statistics—2021 Update: A Report from the American Heart Association. Circulation, 143, e254-e743. [Google Scholar] [CrossRef
[3] 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2021概要[J]. 心脑血管病防治, 2022, 22(4): 20-36, 40.
[4] 王倩. 替格瑞洛联合阿托伐他汀治疗急性冠脉综合征的临床效果探究[J]. 基层医学论坛, 2023, 27(1): 68-70.
[5] 张新超, 于学忠, 陈凤英, 等. 急性冠脉综合征急诊快速诊治指南(2019) [J]. 临床急诊杂志, 2019, 20(4): 253-262.
[6] Toyoda, S., Takekawa, H., Asa-kawa, Y., et al. (2018) Comparison of Carotid Artery Ultrasonography Findings between Acute Coronary Syndrome and Atherothrombotic Cerebral Infarction. Journal of Medical Ultrasonics, 45, 149-154. [Google Scholar] [CrossRef] [PubMed]
[7] 董潇玲, 潘甜, 彭学军. 早发急性冠脉综合征的研究进展[J]. 中国实用医药, 2021, 16(32): 200-202.
[8] 王妮. 血栓通注射液对急性冠脉综合征患者介入术后血脂、炎症因子及内皮功能的影响[J]. 现代中西医结合杂志, 2017, 26(7): 728-730.
[9] Aydin, S., Eren, M.N., Yilmaz, M., et al. (2016) Adropin as a Potential Marker of Enzyme-Positive Acute Coronary Syndrome. Cardiovascular Journal of Africa, 28, 40-47. [Google Scholar] [CrossRef
[10] 王志兴, 王国良. 沙库巴曲缬沙坦对经皮冠状动脉介入术后血管内皮功能、心肌损伤和近期预后的影响[J]. 安徽医药, 2021, 25(4): 821-825.
[11] 陈福生, 孙秀成, 杨天伦. 替米沙坦对冠心病病人经皮冠状动脉介入术后心型脂肪酸结合蛋白的影响[J]. 中西医结合心脑血管病杂志, 2020, 18(12): 1932-1934.
[12] 杨淑娟, 梁锦荣, 李盘石, 覃炳军. 血清cTnI、hs-CRP、NT-pro BNP联合检测对急性心肌梗死的诊断价值[J]. 山东医药, 2020, 60(2): 75-77.
[13] Szunerits, S., Mishyn, V., Grabowska, I. and Boukherroub, R. (2019) Electrochemical Cardiovascular Platforms: Current State of the Art and beyond. Biosensors and Bioelectronics, 131, 287-298. [Google Scholar] [CrossRef] [PubMed]
[14] 吴宇波, 黄飞雄. 探讨对ACS(急性冠状动脉综合征)患者在实施PCI(经皮冠状动脉介入)治疗期间给予替格瑞洛治疗的可行性[J]. 中西医结合心血管病电子杂志, 2020, 8(26): 56-57.
[15] 段云鹏, 刘娜, 马志刚, 张家安. 血清LP-PLA2、cTnⅠ及LOX-1对老年急性冠脉综合征患者早期诊断的价值分析[J]. 中国免疫学杂志, 2020, 36(13): 1636-1640.
[16] Chapman, A.R., Fujisawa, T., Lee, K.K., et al. (2018) Novel High-Sensitivity Cardiac Troponin I Assay in Patients with Suspected Acute Coronary Syndrome. Heart, 105, 616-622. [Google Scholar] [CrossRef] [PubMed]
[17] 游志刚, 黄琳, 姜醒华. 联合检测CRP、BNP和cTnI在急性心肌梗死患者中的临床意义[J]. 热带医学杂志, 2015, 15(1): 56-58.
[18] Sethwala, A.M., Goh, I. and Amerena, J.V. (2020) Combating Inflammation in Cardiovascular Disease. Heart, Lung and Circulation, 30, 197-206. [Google Scholar] [CrossRef] [PubMed]
[19] 曹亮亮, 严卫国. 心电图联合脑钠肽前体、肌钙蛋白T对早期急性心肌梗死的诊断价值[J]. 中国医药导报, 2022, 19(2): 67-70.
[20] Huang, H.Z., Yu, Y.R., Chen, L.L., et al. (2021) Independent and Joint Effects of High-Sensitivity C-Reactive Protein and Hypoalbuminemia on Long-Term All-Cause Mortality among Coronary Artery Disease: A Prospective and Multicenter Cohort Study. BMC Cardiovascu-lar Disorders, 21, Article No. 613. [Google Scholar] [CrossRef] [PubMed]
[21] 郭岑, 周白丽. 西宁地区ACS患者血清APN、hs-CRP含量与冠脉病变严重程度的关系[J]. 现代临床医学, 2020, 46(6): 419-421, 424.
[22] 柯慧慧, 段迎春, 胡花, 等. HMGB1/TLR4在卵巢癌中的表达及其与临床病理特征的关系[J]. 中国妇幼保健, 2018, 33(10): 2349-2353.
[23] Davlouros, P., Xanthopoulou, I., Goudevenos, J., et al. (2017) Contemporary Antiplatelet Treatment in Acute Coronary Syndrome Patients with Impaired Renal Function Undergoing Percutaneous Coronary Intervention. Cardiology, 138, 186-194. [Google Scholar] [CrossRef] [PubMed]
[24] Jia, C., Zhang, J., Chen, H.W., et al. (2019) Endothelial Cell Pyroptosis Plays an Important Role in Kawasaki Disease via HMGB1/RAGE/Cathespin B Signaling Pathway and NLRP3 Inflammasome Activation. Cell Death & Disease, 10, Article No. 778. [Google Scholar] [CrossRef] [PubMed]
[25] 张英武, 段军仓, 陈少泽, 瞿德涛. PCI术对老年急性冠状动脉综合征患者血清HMGB1与SAA水平表达的影响[J]. 重庆医学, 2018, 47(18): 2510-2512.
[26] Rath, D., Geisler, T., Gawaz, M. and Vogel, S. (2017) HMGB1 Expression Level in Circulating Platelets Is Not Significantly As-sociated with Outcomes in Symptomatic Coronary Artery Disease. Cellular Physiology and Biochemistry, 43, 1627-1633. [Google Scholar] [CrossRef] [PubMed]
[27] Raucci, A., Di Maggio, S., Scavello, F., et al. (2019) The Janus face of HMGB1 in Heart Disease: A Necessary Update. Cellular and Molecular Life Sciences, 76, 211-229. [Google Scholar] [CrossRef] [PubMed]
[28] Kohno, T., Anzai, T., Naito, K., et al. (2008) Role of High-Mobility Group Box 1 Protein in Post-Infarction Healing Process and Left Ventricular Remodelling. Cardiovascu-lar Research, 813, 565-573. [Google Scholar] [CrossRef] [PubMed]
[29] 江文科, 程卓, 李锦良, 张光平. 急性冠脉综合征患者血清HMGB1、cTnI、BNP、hs-CRP表达及其诊断价值[J]. 海南医学, 2020, 31(12): 1530-1533.
[30] 高海超, 韩婷婷, 王虹. 血清HMGB1、sCD40L对急性冠脉综合征病情及经皮冠脉介入术预后的评估价值[J]. 临床和实验医学杂志, 2022, 21(9): 937-941.
[31] 郭向伊, 刘威, 程建新. NSTEMI患者GRACE评分与cTnI、BNP、GA水平相关性及其预测价值[J]. 河北医科大学学报, 2020, 41(5): 506-509.
[32] Suzuki, T., Yamazaki, T. and Yazaki, Y. (2001) The Role of the Natriuretic Peptides in the Cardiovascular System. Cardiovascular Research, 513, 489-494. [Google Scholar] [CrossRef
[33] 何汉康, 叶巍, 陈剑, 等. 血清脑钠尿肽、氨基末端脑钠尿肽前体、血管紧张素(1-7)水平与急性冠状动脉综合征患者心功能和预后的关系[J]. 中华高血压杂志, 2020, 28(5): 470-474.
[34] 李富利, 赵艳军, 于健, 王一冰. 血浆Hcy、BNP、CK-MB联合检测在急性冠脉综合征患者预后评价中的价值[J]. 河北医药, 2021, 43(3): 394-396, 400.
[35] 鞠丹丹, 张玥, 国莉莉, 张艳艳. ACS患者血清GGT、BNP及CRP水平与冠状动脉病变程度的关系[J]. 分子诊断与治疗杂志, 2022, 14(1): 137-140.